Cite
HARVARD Citation
Usmani, S. et al. (2016). Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma. Journal of medical economics. pp. 243-258. [Online].